Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study

NCT00546845 | Unknown Phase 4

• 1 other identifier: XXS
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

This study is an investigator-initiated study. The study will be performed as a prospective, randomized, controlled multi-center trial to evaluate the safety and efficiency of Xpert stents compared to PTA in patients with chronic distal artery occlusions or stenosis undergoing catheter revascularization. Patients will be eligible for randomization if they are over 18 years old, if they undergo percutaneous catheter revascularization of an artery below the knee stenosis/occlusion that is less than 15 centimeters in length. Up to two vessels may be treated in this study. All lesions greater than 50% in the below the knee artery region have to be treated either with PTA or stenting according to the randomization.

Conditions

Cronic Limb Ishemia; Intervention

Outcome Measures

Primary Outcomes (1)

• MLD at the target lesion assessed by angiography

  treatment effect dependent if stent of PTA was choosen

  after 12 +/-2 months

Secondary Outcomes (4)

• 1. Interventional success rate. Interventional success is defined as restenosis less than 50%. 2. Late lumen loss (LLL)

  after 1, 6, 12 months and 3 years

• 3. Binary restenosis

  arter 6, 12 months and 3 years

• 4. Number of patients initially randomized to the PTA group, but receiving stents because of the suboptimal interventional success.

  intervention

• Target lesion revascularization, clinical stage, hospital days

  after 1, 6, 12 months, and 3 years

Interventions

Balloon angioplasty DEVICE

Balloon angioplasty. Only stent if PTA fails

Use of self-expanding Expert stent DEVICE

Nitinol stent

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical:
• \. Age between 18 and 95 years. 2. Subject or subject's legal representative have been informed of the nature of the study, and have signed the patient informed consent form. Patient is willing to take part in the follow-up protocol of the XXS study.
• \. Rutherford stage 4 and 5 Anatomical:
• Additional lesions inflow lesions might be successfully treated before randomization and treatment of the target lesion. The inflow lesions which were treated before randomization should only be classified TASC A or B. (TASC= Trans Atlantic Intersociety Conference)
• Target vessel with documented run-off to the foot distally of the index lesion with patent plantar arteries
• Reference vessel diameter of the target lesion should be ≥ 2 and ≤ 5 mm.
• Maximum treated length in the target vessel is 15 cm (might also be divided up into multiple segments with up to 3 different lesions being treated).
• Maximum of treated vessels per leg below the knee: 2 (all treated vessels should be treated within the randomization to the study group \[PTA or stenting\]).
• Minimum distance target lesion to talus is 5 cm.

You may not qualify if:

• Clinical
• Life expectancy due to a non-atheroslerotic disease less than 12 months.
• Previous bypass surgery \< 30 days prior to the study procedure.
• Known allergies or sensitivities to heparin, contrast media, aspirin, clopidogrel, and nitinol which cannot be treated with antihistamines.
• eGFR less than 29 mL/min/1.73m2 (K-DOQI Class 4 and 5) in patients which are not currently treated with dialysis (equivalent to a serum creatinine level of 2.4 mg/dL in a 70 year old male patient)
• Subject with breast feeding plans, or child bearing potential with no birth control.
• Subjects enrolled in another study concerning the index vessel(s) within 3 months prior to the study procedure.
• Untreatable bleeding diatheses.
• Patients who have an indication of being treated with coumadin after the intervention.
• Inability to ambulate
• Hypercoagulable state
• Patients with age \<18 years and patients who are not able to sign the informed consent form
• Anatomical:
• Inflow is obstructed and cannot be successfully treated prior to randomization and treatment of below the knee arteries.
• Acute thrombus present in the target limb.

Sponsors & Collaborators

• University Hospital Tuebingen: lead

Study Sites (1)

Universtiy of Tuebingen

Tübingen, Baden-Wurttemberg, 72076, Germany

RECRUITING

MeSH Terms

Interventions

Angioplasty, Balloon

Intervention Hierarchy (Ancestors)

Angioplasty; Catheterization; Therapeutics; Endovascular Procedures; Vascular Surgical Procedures; Cardiovascular Surgical Procedures; Surgical Procedures, Operative; Minimally Invasive Surgical Procedures; Investigative Techniques

Study Officials

• Gunnar Tepe, MD

  University Hospital Tuebingen

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gunnar Tepe, MD

CONTACT

49 7071 2983371; gunnar.tepe@med.uni-tuebingen.de

Jane Gollub

CONTACT

49 7071 2983371; jane.gollub@med.uni-tuebingen.de

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: October 17, 2007
• First Posted: October 19, 2007
• Study Start: September 1, 2007
• Primary Completion: March 1, 2012
• Study Completion: June 1, 2014
• Last Updated: August 8, 2011

Record last verified: 2007-10

Locations

DE (1)